Cohance Lifesciences Ltd. News and Updates

Name: Latest research reports of Cohance Lifesciences Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Cohance Lifesciences Ltd.
Rating: 5
Author: ICICI Securities Limited

Keep track of all breaking news on Cohance Lifesciences Ltd. from all sources in a single place.

Cohance Lifesciences Ltd.

08 Apr 2025

1075.20

1.87%

Broker's call: Suven Pharma (Buy)

Business Line

Goldman Sachs

Cohance Lifesciences Ltd. has gained 66.52% in the last 1 Year

Cohance Lifesciences Ltd.

29 Mar 2025

1075.20

1.87%

Suven Pharma Eyes $1-Billion Revenue By 2030, Driven By CDMO Expansion

NDTV Profit

Executive Chairman Vivek Sharma said that Suven Pharmaceuticals remains optimistic about its business trajectory, particularly in the high-growth CDMO sector.

Cohance Lifesciences Ltd. has gained 66.52% in the last 1 Year

NCLT approves amalgamation of Suven Pharma, Cohance Lifesciences

Business Standard | 28 Mar 2025 1 more

Cohance Lifesciences Ltd.

25 Mar 2025

1075.20

1.87%

Suven Pharma Gets 'Buy' On ICICI Securities Initiation, Sees 19% Upside

NDTV Profit

ICICI Securities initiates coverage on Suven Pharma with a Buy rating and a target price of Rs 1,400 (upside of ~19%).

Cohance Lifesciences Ltd. has gained 66.52% in the last 1 Year

Cohance Lifesciences Ltd.

25 Mar 2025

1075.20

1.87%

A distinct CDMO in the making

Buy: Cohance Lifesciences Ltd.

Recommendation Target

ICICI Securities Limited

Suven’s rapid ascendance in the CDMO space has been remarkable. It has journeyed from being a small molecule-focused CDMO to achieving eminence as one of the few CDMOs in India that offers contract manufacturing of oligonucleotides and ADCs.

Cohance Lifesciences Ltd. has gained 66.52% in the last 1 Year

Cohance Lifesciences Ltd.

24 Mar 2025

1075.20

1.87%

[Initiation] A play on the ADC growth segment

Buy: Cohance Lifesciences Ltd.

BOB Capital Markets Ltd.

ADC is an evolving second line of treatment in oncology. The company expects market size to grow to US$ 50bn by FY33 from US$ 5bn in FY22

Cohance Lifesciences.. has an average target of 1402.50 from 2 brokers.

Cohance Lifesciences Ltd.

03 Mar 2025

1075.20

1.87%

Indian pharma's capability, regulatory compliance help to tap global CDMO space'

Business Line

The progress India has made in terms of building the capabilities and number of scientists work in its favour.Also, India has a much better regulatory record than how it was perceived about 7 and 8 years ago': Suven Pharma's Executive Chairman Vivek Sharma

Cohance Lifesciences.. has an average target of 1402.50 from 2 brokers.

Cohance Lifesciences Ltd.

20 Feb 2025, 02:37PM

1075.20

1.87%

Suven Pharma soars 14% on heavy volumes; surges 43% from January low

Business Standard

Suven Pharma is set to benefit from high-growth cutting-edge CDMO segments and its proven track record to drive traditional business.

Number of FII/FPI investors increased from 201 to 218 in Mar 2025 qtr.

Cohance Lifesciences Ltd.

20 Feb 2025, 12:06PM

1075.20

1.87%

Macquarie initiates outperform rating on 4 Indian pharma stocks, sees 19-35% upside. Here's why

livemint

Indian pharma stocks: Macquarie favours Indian CDMOs, notably Divi's Labs and Suven Pharma, highlighting their superior scale and customer relationships. The Indian CRDMO market is projected to grow from US$7 billion to US$14 billion by 2028, driven by increased pharmaceutical outsourcing.

Cohance Lifesciences.. has an average target of 1402.50 from 2 brokers.

Macquarie bullish on Suven Pharma, Divi's Labs, Bluejet and Syngene

Economic Times | 20 Feb 2025, 05:29AM

Cohance Lifesciences Ltd.

13 Feb 2025

1075.20

1.87%

Suven Pharma shares zooms 12% on strong Q3 nos; PAT up 78%, rev 39%

Business Standard

Suven Pharma reported a 78 per cent rise in consolidated net profit during the third quarter to Rs 83.29 crore, as compared to Rs 46.75 crore in Q3FY24